Thibault Mesplede

Rotterdam, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 111 publications

Understanding the Clinical Implications of the Barrier Against Resistance in Antiretroviral Treatment.

Understanding the Clinical Implications of the Barrier Against Resistance in Antiretroviral Treatment.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: April 08, 2026

Two cases of possible transmitted HIV drug resistance to all currently available integrase inhibitors, the Netherlands, 2025.

Two cases of possible transmitted HIV drug resistance to all currently available integrase inhibitors, the Netherlands, 2025.

Journal: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

Published: February 27, 2026

HIV-1 reservoir inducibility and immune phenotypes after prolonged analytical treatment interruption: a long-term follow-up study.

HIV-1 reservoir inducibility and immune phenotypes after prolonged analytical treatment interruption: a long-term follow-up study.

Journal: EBioMedicine

Published: January 26, 2026

HIV-1 and HIV-2 interaction results in reduced cell infectivity and viral replication in vitro.

HIV-1 and HIV-2 interaction results in reduced cell infectivity and viral replication in vitro.

Journal: Virology journal

Published: September 04, 2025

HIV-1 and HIV-2 interaction results in reduced cell infectivity and viral replication in vitro.

HIV-1 and HIV-2 interaction results in reduced cell infectivity and viral replication in vitro.

Journal: Virology journal

Published: September 04, 2025

Cooperation between HIV-1 integrase natural polymorphism K156N and 3'PPT mutations in dolutegravir monotherapy failure.

Cooperation between HIV-1 integrase natural polymorphism K156N and 3'PPT mutations in dolutegravir monotherapy failure.

Journal: The Journal of antimicrobial chemotherapy

Published: August 14, 2025

How frequent is dolutegravir resistance?

How frequent is dolutegravir resistance?

Journal: Expert review of anti-infective therapy

Published: July 07, 2025

Emergent HIV-1 Drug Resistance in Randomized Trials of Contemporary Antiretroviral Regimens.

Emergent HIV-1 Drug Resistance in Randomized Trials of Contemporary Antiretroviral Regimens.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: June 07, 2025

Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered Questions.

Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered Questions.

Journal: Open forum infectious diseases

Published: March 12, 2025

Computational and Population-Based HLA Permissiveness to HIV Drug Resistance-Associated Mutations.

Computational and Population-Based HLA Permissiveness to HIV Drug Resistance-Associated Mutations.

Journal: Pathogens (Basel, Switzerland)

Published: January 30, 2025

Insights to a Cure: Unique Controller Phenotypes in the Rotterdam HIV-2 Cohort.

Insights to a Cure: Unique Controller Phenotypes in the Rotterdam HIV-2 Cohort.

Journal: Open forum infectious diseases

Published: December 12, 2024

Novel Dolutegravir and Lenacapavir Resistance Patterns in Human Immunodeficiency Virus Type 2 Infection: A Case Report.

Novel Dolutegravir and Lenacapavir Resistance Patterns in Human Immunodeficiency Virus Type 2 Infection: A Case Report.

Journal: Open forum infectious diseases

Published: November 13, 2024

Showing 1-12 of 111

Last Updated: 09/26/2026